|
Acomplia (Rimonabant) is a new diet pill that has been developed in France, and it is quickly causing a buzz among dieters
in all parts of the world. Originally developed to help people stop smoking, Acomplia also appears to suppress appetite by
blocking hunger signals to the brain.
The French company Sanofi-Synthelabo is the creator of Accomplia, which it intends to market in the United States by as
early as 2006 and possibly sooner in Europe. Since 2001 the drug has undergone thorough testing with the first animal study
conducted by the National Institute of Health. In that study, genetically altered mice that lacked cannabinoid receptors were
found to eat less than mice with an intact endocannabinoid system. The normal mice were then given Acomplia, and their food
intake significantly decreased as well.
After a year, more than 67 percent of those given a 20 mg dose of Acompleea had lost at least 5% of their original body
weight, with 39% losing 10% of that weight or more. Those taking 5 mg doses of Acomplia lost more weight than those taking
a placebo, but less weight than those taking 20 mg of the drug.
|
